DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Mangalam Drugs And Organics Limited — Change in Management

NSE 2 hrs ago·24 Sept 2026, 1:03 pm

Company NSE

Mangalam Drugs And Organics Limited has informed stock exchanges about a change in its management structure. This typically involves the appointment of a new chief executive officer or other key executives, signaling a potential shift in the company's strategic direction or leadership team.

For investors, such news can be significant as it may lead to changes in the company's operational strategy, focus areas, or long-term growth plans. While a change in management is not inherently negative, it introduces a period of uncertainty regarding the continuity of existing policies and the execution of future business goals.

Investors should closely monitor the company's subsequent announcements regarding the new leadership's vision and the impact of this transition on the company's performance and stock price.